Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.

J Gynecol Oncol · 2022 · PMC9634096 · PMID 36245228

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In addition, our results indicate an increasing trend in the use of TC + bevacizumab as first-line treatment for both patients receiving NAC and those receiving PDS for ovarian cancer.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.